EVI1 and MDS1/EVI1 expression during primary human hematopoietic progenitor cell differentiation into various myeloid lineages

Anticancer Research

Volumn 32, Issue 11, 2012, Pages 4883-4890

  Steinleitner, Katarina ^a   Rampetsreiter, Paulina ^a,c   Köffel, Rene ^b   Ramanathan, Gajalakshmi ^a   Mannhalter, Christine ^a   Strobl, Herbert ^b   Wieser, Rotraud ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

EVI1; Leukemia; Myeloid differentiation; Primary human hematopoietic cells

Indexed keywords

CD14 ANTIGEN; CD15 ANTIGEN; CD34 ANTIGEN; ECOTROPIC VIRAL INTEGRATION SITE 1 PROTEIN; MESSENGER RNA; MYELODYSPLASTIC SYNDROME 1 PROTEIN; ONCOPROTEIN; UNCLASSIFIED DRUG;

ANTIGEN DETECTION; APOPTOSIS; ARTICLE; BONE MARROW CELL; CELL DIFFERENTIATION; CELL LINEAGE; CONTROLLED STUDY; DENDRITIC CELL; ERYTHROID CELL; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION; GRANULOCYTE; HEMATOPOIETIC CELL; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; MEGAKARYOCYTE; MONOCYTE; ONCOGENE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RETROVIRUS INFECTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENESCENCE;

ANTIGENS, CD34; CELL DIFFERENTIATION; CELL LINEAGE; DNA-BINDING PROTEINS; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELLS; HUMANS; PROTO-ONCOGENES; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSCRIPTION FACTORS; U937 CELLS;

EID: 84872667864     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Nanjundan M, Nakayama Y, Cheng K, Lahad J, Liu J, Lu K, Kuo W, Smith-McCune K, Fishman D, Gray J and Mills G: Amplification of MDS1/EVI1 and EVI1, located in the 3q26.2 amplicon, is associated with favorable patient prognosis in ovarian cancer. Cancer Res 67: 3074-3084, 2007.
2. Haas K, Kundi M, Sperr W, Esterbauer H, Ludwig W, Ratei R, Koller E, Gruener H, Sauerland C, Fonatsch C, Valent P and Wieser R: Expression and prognostic significance of different mRNA 5′-end variants of the oncogene EVI1 in 266 patients with de novo AML: EVI1 and MDS1/EVI1 overexpression both predict short remission duration. Genes Chromosomes Cancer 47: 288-298, 2008.
3. Lugthart S, van Drunen E, van Norden Y, van Hoven A, Erpelinck C, Valk P, Beverloo H, Lowenberg B and Delwel R: High EVI1 levels predict adverse outcome in acute myeloid leukemia: Prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated. Blood 111: 4329-4337, 2008.
4. Yatsula B, Lin S, Read A, Poholek A, Yates K, Yue D, Hui P and Perkins A: Identification of binding sites of EVI1 in mammalian cells. J Biol Chem 280: 30712-30722, 2005.
5. Bard-Chapeau E, Jeyakani J, Kok C, Muller J, Chua B, Gunaratne J, Batagov A, Jenjaroenpun P, Kuznetsov V, Wei C, D'Andrea R, Bourque G, Jenkins N and Copeland N: Ecotopic viral integration site 1 (EVI1) regulates multiple cellular processes important for cancer and is a synergistic partner for FOS protein in invasive tumors. Proc Natl Acad Sci USA 109: 2168-2173, 2012.
6. Wieser R: The oncogene and developmental regulator EVI1: Expression, biochemical properties, and biological functions. Gene 396: 346-357, 2007.
7. Yuasa H, Oike Y, Iwama A, Nishikata I, Sugiyama D, Perkins A, Mucenski M, Suda T and Morishita K: Oncogenic transcription factor Evi1 regulates hematopoietic stem cell proliferation through GATA-2 expression. EMBO J 24: 1976-1987, 2005.
8. Goyama S, Yamamoto G, Shimabe M, Sato T, Ichikawa M, Ogawa S, Chiba S and Kurokawa M: Evi-1 is a critical regulator for hematopoietic stem cells and transformed leukemic cells. Cell Stem Cell 3: 207-220, 2008.
9. Laricchia-Robbio L and Nucifora G: Significant increase of self-renewal in hematopoietic cells after forced expression of EVI1. Blood Cells Mol Dis 40: 141-147, 2008.
10. Kataoka K, Sato T, Yoshimi A, Goyama S, Tsuruta T, Kobayashi H, Shimabe M, Arai S, Nakagawa M, Imai Y, Kumano K, Kumagai K, Kubota N, Kadowaki T and Kurokawa M: Evi1 is essential for hematopoietic stem cell self-renewal, and its expression marks hematopoietic cells with long-term multilineage repopulating activity. J Exp Med 208: 2403-2416, 2011.
11. Buonamici S, Li D, Chi Y, Zhao R, Wang X, Brace L, Ni H, Saunthararajah Y and Nucifora G: Evi1 induces myelodysplastic syndrome in mice. J Clin Invest 114: 713-719, 2004.
12. Shimizu S, Nagasawa T, Katoh O, Komatsu N, Yokota J and Morishita K: EVI1 is expressed in megakaryocyte cell lineage and enforced expression of EVI1 in UT-7/GM cells induces megakaryocyte differentiation. Biochem Biophys Res Commun 292: 609-616, 2002.
13. Konrad T, Karger A, Hackl H, Schwarzinger I, Herbacek I and Wieser R: Inducible expression of EVI1 in human myeloid cells causes phenotypes consistent with its role in myelodysplastic syndromes. J Leukoc Biol 86: 813-822, 2009.
14. Ichihara E, Kaneda K, Saito Y, Yamakawa N and Morishita K: Angiopoietin1 contributes to the maintenance of cell quiescence in EVI1(high) leukemia cells. Biochem Biophys Res Commun 416: 239-245, 2011.
15. Yamakawa N, Kaneda K, Saito Y, Ichihara E and Morishita K: The increased expression of integrin alpha 6 (ITGA6) enhances drug resistance in EVI1(high) leukemia. PLoS One 7: e30706, 2012.
16. Taschner S, Koesters C, Platzer B, Jorgl A, Ellmeier W, Benesch T and Strobl H: Down-regulation of RXRalpha expression is essential for neutrophil development from granulocyte/monocyte progenitors. Blood 109: 971-979, 2007.
17. Vinatzer U, Mannhalter C, Mitterbauer M, Gruener H, Greinix H, Schmidt H, Fonatsch C and Wieser R: Quantitative comparison of the expression of EVI1 and its presumptive antagonist, MDS1/EVI1, in patients with myeloid leukemia. Genes Chromosomes Cancer 36: 80-89, 2003.
18. Livak K and Schmittgen T: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25: 402-408, 2001.
19. Scicchitano M, McFarland D, Tierney L, Narayanan P and Schwartz L: In vitro expansion of human cord blood CD36(+) erythroid progenitors: Temporal changes in gene and protein expression. Exp Hematol 31: 760-769, 2003.
20. + cells from human cord blood induced by thrombopoietin. Tohoku J Exp Med 192: 259-273, 2000.
21. Dickstein J, Senyuk V, Premanand K, Laricchia-Robbio L, Xu P, Cattaneo F, Fazzina R and Nucifora G: Methylation and silencing of miRNA-124 by EVI1 and self-renewal exhaustion of hematopoietic stem cells in murine myelodysplastic syndrome. Proc Natl Acad Sci USA 107: 9783-9788, 2010.
22. 0/1 phase. Cell Cycle 11: 3492-3503, 2012.
23. Kreider B, Orkin S and Ihle J: Loss of erythropoietin responsiveness in erythroid progenitors due to expression of the Evi-1 myeloid-transforming gene. Proc Natl Acad Sci USA 90: 6454-6458, 1993.
24. Kurokawa M, Mitani K, Yamagata T, Takahashi T, Izutsu K, Ogawa S, Moriguchi T, Nishida E, Yazaki Y and Hirai H: The Evi- 1 oncoprotein inhibits c-Jun N-terminal kinase and prevents stress-induced cell death. EMBO J 19: 2958-2968, 2000.
25. Blagosklonny M: A node between proliferation, apoptosis, and growth arrest. Bioessays 21: 704-709, 1999.
26. Sebastian T and Johnson P: Stop and go: Antiproliferative and mitogenic functions of the transcription factor C/EBPbeta. Cell Cycle 5: 953-957, 2006.